Liege (Belgium) – May 30, 2007, 8:00 am CET – OncoMethylome Sciences announced today that its commercial partner Veridex, LLC, granted a license to Laboratory Corporation of America® Holdings (LabCorp®) which permits LabCorp to commercialize nucleic acid testing technology for detecting the presence of a key tissue marker in prostate cancer, methylated GST-Pi.
